Expand AIM Menu
AIM MENU

AIM Latest Press Releases

-- April 4, 2025 --

AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal Globe Newswire 4:45 PM

-- March 27, 2025 --

AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Globe Newswire 8:05 AM

-- March 11, 2025 --

Virtual Investor Releases Next Wave of "Top 5 for '25" On-Demand Videos ACCESS Newswire 8:46 AM
AIM ImmunoTech Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference Globe Newswire 8:45 AM

-- February 28, 2025 --

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza Globe Newswire 8:45 AM

-- February 26, 2025 --

AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance Globe Newswire 1:20 PM
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director Globe Newswire 8:30 AM

-- February 25, 2025 --

AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer Globe Newswire 8:30 AM

-- February 11, 2025 --

AIM ImmunoTech Releases Virtual Investor "What This Means Segment" Globe Newswire 8:45 AM
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 Globe Newswire 8:30 AM

-- February 7, 2025 --

AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen and AstraZeneca's FluMist to address the recent avian influenza outbreaks Globe Newswire 8:50 AM

-- February 5, 2025 --

Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer Globe Newswire 8:00 AM

-- January 23, 2025 --

AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions Globe Newswire 8:50 AM

-- January 22, 2025 --

AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS Globe Newswire 8:30 AM

-- January 15, 2025 --

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones Globe Newswire 9:05 AM

-- December 17, 2024 --

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards Globe Newswire 4:45 PM
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting Business Wire 3:10 PM

-- December 16, 2024 --

AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy Card Business Wire 8:00 AM

-- December 14, 2024 --

Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board Globe Newswire 4:54 PM

-- December 12, 2024 --

AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board Members Business Wire 3:00 PM
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue Globe Newswire 9:00 AM
Kellner Group Announces Support from Another Former AIM Senior Executive Globe Newswire 8:16 AM

-- December 10, 2024 --

Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell Business Wire 10:20 AM
Ampligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are Elected Globe Newswire 7:30 AM

-- December 6, 2024 --

AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment Globe Newswire 9:15 AM
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Globe Newswire 8:34 AM

-- December 5, 2024 --

ISS Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan and Dr. William M. Mitchell Business Wire 9:00 AM

-- December 2, 2024 --

AIM ImmunoTech Issues Presentation Detailing Why Shareholders Should NOT Elect Activist Group's Nominees to the Board Business Wire 8:00 AM
Kellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Globe Newswire 7:30 AM

-- November 27, 2024 --

AIM ImmunoTech Refutes Activist Group's False and Misleading Claims Business Wire 3:30 PM
AIM ImmunoTech Announces Cash Conservation Plan Business Wire 8:00 AM

-- November 26, 2024 --

Kellner Group Urges Stockholders of AIM Immunotech to Vote Enclosed Gold Card Globe Newswire 7:00 AM

-- November 25, 2024 --

AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders Business Wire 8:00 AM

-- November 20, 2024 --

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board PRNewswire 11:50 AM

-- November 19, 2024 --

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer Globe Newswire 8:00 AM
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board Globe Newswire 7:00 AM

-- November 15, 2024 --

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update Globe Newswire 7:29 AM

-- November 14, 2024 --

Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board PRNewswire 9:00 AM

-- November 6, 2024 --

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast Globe Newswire 9:00 AM